Insulet Corporation announced the departure of two Board members on September 3, 2026. Timothy J. Scannell stepped down for health reasons effective immediately after serving 12 years, including seven as Chairman. Michael R. Minogue also resigned to focus on his candidacy for Governor of Massachusetts, with an effective date of September 15, 2026, following nine years of service. Neither director cited disagreements regarding operations or policies as the reason for their exit. Insulet Corporation operates in the medical device industry, specializing in insulin delivery systems.

Insulet Corporation reported second quarter 2026 financial results, announcing revenue of $801.7 million, a 23.5% increase from the prior year period. Net income rose to $95.0 million, or $1.37 per diluted share, compared to $22.5 million in the previous year. The company updated its full-year 2026 revenue growth guidance downward to 20%-22% at constant currency, reflecting scaling dynamics in type 2 diabetes markets. Insulet operates as a medical device company specializing in tubeless insulin pump technology and automated insulin delivery systems.

Insulet Corporation appointed Jonathan J. Mazelsky as a Class II director, effective July 1, 2026. Mr. Mazelsky, formerly the CEO of IDEXX Laboratories, Inc., will receive an initial grant of restricted stock units worth $216,548. Insulet Corporation is a medical technology company that develops and manufactures continuous glucose monitoring systems and insulin delivery systems.